Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | PARG | Q86W56 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22392263 | 0.90 | KDM4E (0.62) | KDM4EAHRHIF1AALDH1A1HPGD | |
| SCHEMBL20893357 | 0.90 | HIF1A (0.71) | KDM4EAHRHIF1APARG | |
| SCHEMBL15714217 | 0.86 | HIF1A (0.58) | KDM4EAHRHIF1AALDH1A1HPGD | |
| SCHEMBL17179762 | 0.86 | KDM4E (0.65) | KDM4EAHRHIF1AALDH1A1HPGD | |
| SCHEMBL2493208 | 0.83 | KDM4E (0.67) | KDM4EAHRHIF1AALDH1A1HPGD | |
| SCHEMBL4593787 | 0.83 | KDM4E (0.70) | KDM4EAHRHIF1AALDH1A1HPGD | |
| SCHEMBL4654283 | 0.82 | HIF1A (0.59) | KDM4EAHRHIF1AALDH1A1HPGD | |
| SCHEMBL1854495 | 0.81 | KDM4E (0.73) | KDM4EAHRHIF1AALDH1A1HPGD | |
| SCHEMBL13102768 | 0.81 | KDM4E (0.67) | KDM4EAHRHIF1AALDH1A1HPGD | |
| SCHEMBL15714261 | 0.80 | PIM1 (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | KDM4E 1688/4885AHR 142/4885HIF1A 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.